We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Hepatorenal syndrome].
Khirurgiia 2002
Functional renal disorders commonly complicate cirrhosis and ascits, and in its terminal stage is known as hepatorenal syndrome (HRS). HRS is defined as the development of renal failure in patients with advanced liver failure (acute or chronic) in the absence of other identifiable causes of renal pathology. It is a syndrome characterized by oliguria, severe renal sodium retention, circulatory instability with marked systemic arterial vasodilatation and activation vasoactive systems. Signs of renal functional impairment may be observed in more than 30% of patients with cirrhosis and ascites, but only about 5% showed typical signs of HRS. In patients with decompensated cirrhosis, HRS has been found in about 18% after 1 year and in 40% after 5 years of follow up. In this survey are showed the diagnostic criteria for HRS as set out by the International Ascites Club. According to this criteria HRS was considered present when serum creatinine was > 1.5 mg/dl and creatinine clearance < 40 ml/min. Several therapeutic approaches have been proposed to modify the altered systematic and renal hemodynamics occurring during HRS. Administration of plasma expanders or vasoconstricting drugs, peritoneovenous shunting, portosystemic shunts and transjugular intrahepatic portosystemic shunts have been used to reverse peripheral vasodilatation and improve vascular underfilling. Renal vasodilatators and prostaglandins have been administered to reduce renal vasoconstriction. Theoretically the ideal treatment for patients with HRS is liver transplantation. The prognosis for HRS is poor and treatment almost always unsatisfactory when liver transplantation is excluded. The best treatment of HRS is preventing precipitating factors.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app